Latest Conference Articles

Watch Dr. Jessica R. Bauman, from Fox Chase Cancer Center, discuss palliative care during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Hossein Borghaei, Dr. David Gerber, Dr. Aaron S. Mansfield and Dana M. Haagen answer questions on the management of advanced/metastatic disease during the CURE Educated Patient Lung Cancer Summit.

Watch Dana Haagen, from Fox Chase Cancer Center, discuss clinical trials and how patients can join them, during the CURE® Educated Patient® Lung Cancer Summit.

Watch Dr. Aaron S. Mansfield, from Mayo Clinic, discuss the management of mesothelioma during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. David Gerber, from UT Southwestern Medical Center, discuss antibody drug conjugates during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Hossein Borghaei, Dr. Jared Weiss and Dr. Anne Chiang answer questions about early disease management during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Anne Chiang, from Yale School of Medicine, discuss molecular testing and adjuvant targeted therapies during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Jared Weiss, from UNC School of Medicine, discuss neoadjuvant versus adjuvant therapy during the CURE Educated Patient Lung Cancer Summit.

CURE®’s Lung Cancer Heroes® Award Program honors and gives thanks to those heroes who have positively affected the lives of patients with lung cancer.

None of the more than 100 evaluable patients with mismatch repair deficient colon cancer have experienced disease recurrence after treatment with presurgical Opdivo plus Yervoy, according to study results.

Treatment with Libtayo may improve survival over a 30-month period with no new side effects in patients with recurrent or metastatic cervical cancer, opening the doors for an immunotherapy option for these patients.

Two years of the hormone treatment androgen-deprivation therapy (ADT) after radiotherapy and radical prostatectomy tended to improve metastasis-free survival for patients with prostate cancer, study results showed.

The use of a tumor-infiltrating lymphocyte therapy led to better outcomes than treatment with Yervoy in patients with unresectable, treatment-refractory stage 3/4 melanoma, a type of skin cancer, study results showed.

With nearly one-year of additional follow-up, adding Keytruda to the combination of abiraterone acetate and the steroid prednisone shows continued benefit in men with metastatic castration-resistant prostate cancer.

The addition of Cabometyx to the current standard-of-care frontline regimen of Opdivo plus Yervoy improved progression-free survival outcomes in patients with advanced kidney cancer.

Lenvima plus Keytruda improved survival outcomes for patients with pretreated advanced endometrial cancer, according to recent clinical trial data.

Adding the novel drug oleclumab to Imfinzi and chemotherapy for the frontline treatment of advanced triple-negative breast cancer did not improve clinical outcomes, according to recent study findings.

Rubraca improved progression-free survival in patients with BRCA1/2-mutant, platinum-sensitive, relapsed ovarian cancer, according to findings from the ARIEL4 clinical trial.

Watch Dr. Ravi Salgia, Dr. Erminia Massarelli, Dr. Jyoti Malhotra and Daniel Saez answer questions about advancements in lung cancer during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Jyoti Malhotra, from City of Hope, discuss advancements in advanced-stage non-small cell lung cancer during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Erminia Massarelli, from City of Hope, discuss advancements in early-stage non-small cell lung cancer during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Ravi Salgia, from City of Hope, discuss advancements in small cell lung cancer during the CURE Educated Patient Lung Cancer Summit.

Watch Nikki Martin, Dr. Ying-Chun Lo and Dr. Hossein Borghaei discuss overcoming barriers to receiving biomarker testing during the CURE Educated Patient Lung Cancer Summit.

Watch Elisabeth King, Dr. Edward S. Kim and Terri Conneran answer questions about targeted therapy during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Edward S. Kim, from City of Hope, discuss targeted therapy during the CURE Educated Patient Lung Cancer Summit.

Watch Elisabeth King, from City of Hope, discuss biomarker testing during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Farhad Mazdisnian, Dr. Terence Williams and Dr. Antoinette J. Wozniak answer questions about the basics of the disease during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Terrance M. Williams, from City of Hope, discuss radiation advances during the CURE Educated Patient Lung Cancer Summit.